- Home
- CHNR vs PULM Comparison
CHNR vs PULM Comparison
Compare CHNR & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHNR | PULM |
|---|---|---|
| Founded | N/A | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.9M |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CHNR | PULM |
|---|---|---|
| Price | $3.72 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 47.6K | 23.2K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $3.16 | $1.16 |
| 52 Week High | $8.20 | $9.00 |
Technical Indicators
Market Signals| Indicator | CHNR | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 42.33 | 56.49 |
| Support Level | $3.35 | $1.21 |
| Resistance Level | $4.12 | $1.44 |
| Average True Range (ATR) | 0.39 | 0.09 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 18.25 | 57.58 |
Price Performance
Historical ComparisonAbout CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).